916420-42-3 Usage
General Description
3-[4-Fluoro-3-(trifluoromethyl)phenyl]propionic acid is a chemical compound with the molecular formula C11H9F4O2. It is a non-steroidal anti-inflammatory drug (NSAID) that is used to relieve pain and reduce inflammation. It works by inhibiting the production of certain chemicals in the body that cause pain and inflammation. 3-[4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]PROPIONIC ACID is commonly used to treat conditions such as arthritis, menstrual pain, and minor injuries. It is available in various forms, including tablets and capsules, and is generally well-tolerated when taken as directed. However, like all NSAIDs, it can have potential side effects and should be used with caution, especially in individuals with pre-existing medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 916420-42-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,6,4,2 and 0 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 916420-42:
(8*9)+(7*1)+(6*6)+(5*4)+(4*2)+(3*0)+(2*4)+(1*2)=153
153 % 10 = 3
So 916420-42-3 is a valid CAS Registry Number.
916420-42-3Relevant articles and documents
5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS
-
Page/Page column 18, (2011/05/08)
The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I) wherein R1, R2, R3, and R4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS
-
Page/Page column 36-37, (2010/01/30)
The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5- a]pyrazine derivatives of formula (I) wherein R1, R2, R3, and R4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
